156 related articles for article (PubMed ID: 31976530)
21. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
22. HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Wang CC; Lai CH; Huang YT; Chao A; Chou HH; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e499-506. PubMed ID: 22889667
[TBL] [Abstract][Full Text] [Related]
23. Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Katanyoo K
J Gynecol Oncol; 2017 Nov; 28(6):e79. PubMed ID: 29027397
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of the expression of Hedgehog proteins in cervical carcinoma FIGO stages I-IV treated with radiotherapy or chemoradiotherapy.
Bohr Mordhorst L; Ahlin C; Sorbe B
Gynecol Oncol; 2014 Nov; 135(2):305-11. PubMed ID: 25158038
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
[TBL] [Abstract][Full Text] [Related]
26. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
[TBL] [Abstract][Full Text] [Related]
27. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
28. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
Hirakawa M; Nagai Y; Inamine M; Kamiyama K; Ogawa K; Toita T; Murayama S; Aoki Y
Gynecol Oncol; 2008 Jan; 108(1):126-9. PubMed ID: 17936344
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
[TBL] [Abstract][Full Text] [Related]
30. Blocking Modification of Eukaryotic Initiation 5A2 Antagonizes Cervical Carcinoma via Inhibition of RhoA/ROCK Signal Transduction Pathway.
Liu X; Chen D; Liu J; Chu Z; Liu D
Technol Cancer Res Treat; 2017 Oct; 16(5):630-638. PubMed ID: 27609633
[TBL] [Abstract][Full Text] [Related]
31. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
32. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
33. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
36. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
[TBL] [Abstract][Full Text] [Related]
37. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.
Song S; Rudra S; Hasselle MD; Dorn PL; Mell LK; Mundt AJ; Yamada SD; Lee NK; Hasan Y
Cancer; 2013 Jan; 119(2):325-31. PubMed ID: 22806897
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
[TBL] [Abstract][Full Text] [Related]
39. The Glasgow Prognostic Score Determined During Concurrent Chemoradiotherapy Is an Independent Predictor of Survival for Cervical Cancer.
Nishida T; Nakamura K; Haraga J; Ogawa C; Kusumoto T; Seki N; Masuyama H; Katayama N; Kanazawa S; Hiramatsu Y
Int J Gynecol Cancer; 2015 Sep; 25(7):1306-14. PubMed ID: 26067860
[TBL] [Abstract][Full Text] [Related]
40. P53 expression as a predictor of recurrence in cervical squamous cell carcinoma.
Brenna SM; Zeferino LC; Pinto GA; Souza RA; Andrade LA; Vassalo J; Martinez EZ; Syrjänen KJ
Int J Gynecol Cancer; 2002; 12(3):299-303. PubMed ID: 12060452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
